Rexulti is a brand name of brexpiprazole, approved by the FDA in the following formulation(s):REXULTI (brexpiprazole - tablet;oral)Manufacturer: OTSUKA Approval date: July 10, 2015 Strength(s): 0.25MG [RLD], 0.5MG [RLD], 1MG [RLD], 2MG [RLD], 3MG [RLD], 4MG [RLD] Has a ...
Rexulti first gained FDA approval on July 10, 2015. Rexulti belongs to the drug class called atypical antipsychotics. Rexulti is availableas a genericunder the name brexpiprazole. The brexpiprazole generic is only approved for depression and schizophrenia in adults, whereas the brand Rexulti is also...
Otsuka and Lundbeck announce the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) of REXULTI® (brexpiprazole) for the treatment of schizophrenia in pediatric patients 13 to 17 years of age. The FDA prev
Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI ® (brexpiprazole) to Treat Schizophrenia in Pediatric Patients Ages 13-17. PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS W...